

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number  
**WO 02/092576 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 239/34**,  
A61K 31/505, C07D 251/42, 239/47, 417/12, 401/12,  
231/40, A61P 29/00

(US). **MOSS, Neil**; 199 Barlow Mountain Road, Ridge-  
field, CT 06877 (US). **REGAN, John, Robinson**; 287  
Rockingstone Avenue, Larchmont, NY 10538 (US).

(21) International Application Number: PCT/US02/14733

(74) Agents: **RAYMOND, Robert, P.** et al.; Boehringer Ingel-  
heim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box  
368, Ridgefield, , CT 06877 (US).

(22) International Filing Date: 8 May 2002 (08.05.2002)

(25) Filing Language: English

(81) Designated States (*national*): AE, AU, BG, BR, CA, CN,  
CO, CZ, EC, EE, HR, HU, ID, IL, IN, JP, KR, LT, LV, MX,  
NO, NZ, PL, RO, SG, SI, SK, UA, UZ, VN, YU, ZA.

(26) Publication Language: English

(30) Priority Data:  
60/291,425 16 May 2001 (16.05.2001) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE, TR).

(71) Applicant: **BOEHRINGER INGELHEIM PHAR-  
MACEUTICALS, INC.** [US/US]; Raymond, Robert, P.,  
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridge-  
bury Road, P.o.box 368, Ridgefield, CT 06877-0368 (US).

**Published:**

— with international search report

(72) Inventors: **CIRILLO, Pier, F.**; 180 Washington Road,  
Woodbury, CT 06798 (US). **GOLDBERG, Daniel, R.**;  
31 Highland Avenue, Redding, CT 06896 (US). **HAM-  
MACH, Abdelhakim**; 8 Rolf's Drive, Danbury, CT 06810

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS

(57) Abstract: Disclosed are diarylurea derivatives useful in pharmaceutic compositions for treating diseases or pathological con-  
ditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

WO 02/092576 A1

DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTSAPPLICATION DATA

This application claims benefit to US provisional application no. 60/291,425 filed May 16, 2001.

TECHNICAL FIELD OF THE INVENTION

This invention relates to novel compounds which possess anticytokine activity. The compounds of the invention are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. This invention also relates to processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

BACKGROUND OF THE INVENTION

Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are important biological entities collectively referred to as proinflammatory cytokines. These, along with several other related molecules, mediate the inflammatory response associated with the immunological recognition of infectious agents. The inflammatory response plays an important role in limiting and controlling pathogenic infections.

Elevated levels of proinflammatory cytokines are also associated with a number of diseases of autoimmunity such as toxic shock syndrome, rheumatoid arthritis, osteoarthritis, diabetes and inflammatory bowel disease (Dinarello, C.A., *et al.*, 1984, *Rev. Infect. Disease* 6:51). In these diseases, chronic elevation of inflammation exacerbates or causes much of the pathophysiology observed. For example, rheumatoid synovial tissue becomes invaded with inflammatory cells that result in destruction to cartilage and bone (Koch, A.E., *et al.*, 1995, *J. Invest. Med.* 43: 28-38). Studies suggest that inflammatory changes mediated by cytokines may be involved in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty (PTCA) (Tashiro, H., *et*

*al.*, 2001 Mar, *Coron Artery Dis* 12(2):107-13). An important and accepted therapeutic approach for potential drug intervention in these diseases is the reduction of proinflammatory cytokines such as TNF (also referred to in its secreted cell-free form as TNF $\alpha$ ) and IL-1 $\beta$ . A number of anti-cytokine therapies are currently in clinical trials.

5 Efficacy has been demonstrated with a monoclonal antibody directed against TNF $\alpha$  in a number of autoimmune diseases (Heath, P., "CDP571: An Engineered Human IgG4 Anti-TNF $\alpha$  Antibody" IBC Meeting on Cytokine Antagonists, Philadelphia, PA, April 24-5, 1997). These include the treatment of rheumatoid arthritis, Crohn's disease and ulcerative colitis (Rankin, E.C.C., *et al.*, 1997, *British J. Rheum.* 35: 334-342 and Stack, 10 W.A., *et al.*, 1997, *Lancet* 349: 521-524). The monoclonal antibody is thought to function by binding to both soluble TNF $\alpha$  and to membrane bound TNF.

A soluble TNF $\alpha$  receptor has been engineered that interacts with TNF $\alpha$ . The approach is similar to that described above for the monoclonal antibodies directed against TNF $\alpha$ ;  
15 both agents bind to soluble TNF $\alpha$ , thus reducing its concentration. One version of this construct, called Enbrel (Immunex, Seattle, WA) recently demonstrated efficacy in a Phase III clinical trial for the treatment of rheumatoid arthritis (Brower *et al.*, 1997, *Nature Biotechnology* 15: 1240). Another version of the TNF $\alpha$  receptor, Ro 45-2081 (Hoffman-LaRoche Inc., Nutley, NJ) has demonstrated efficacy in various animal models  
20 of allergic lung inflammation and acute lung injury. Ro 45-2081 is a recombinant chimeric molecule constructed from the soluble 55 kDa human TNF receptor fused to the hinge region of the heavy chain IgG1 gene and expressed in eukaryotic cells (Renzetti, *et al.*, 1997, *Inflamm. Res.* 46: S143).

25 IL-1 has been implicated as an immunological effector molecule in a large number of disease processes. IL-1 receptor antagonist (IL-1ra) had been examined in human clinical trials. Efficacy has been demonstrated for the treatment of rheumatoid arthritis (Anril, Amgen). In a phase III human clinical trial IL-1ra reduced the mortality rate in patients with septic shock syndrome (Dinarello, 1995, *Nutrition* 11, 492). Osteoarthritis  
30 is a slow progressive disease characterized by destruction of the articular cartilage. IL-1 is detected in synovial fluid and in the cartilage matrix of osteoarthritic joints.

Antagonists of IL-1 have been shown to diminish the degradation of cartilage matrix components in a variety of experimental models of arthritis (Chevalier, 1997, *Biomed Pharmacother.* 51, 58). Nitric oxide (NO) is a mediator of cardiovascular homeostasis, neurotransmission and immune function; recently it has been shown to have important effects in the modulation of bone remodeling. Cytokines such as IL-1 and TNF are potent stimulators of NO production. NO is an important regulatory molecule in bone with effects on cells of the osteoblast and osteoclast lineage (Evans, *et al.*, 1996, *J Bone Miner Res.* 11, 300). The promotion of beta-cell destruction leading to insulin dependent diabetes mellitus shows dependence on IL-1. Some of this damage may be mediated through other effectors such as prostaglandins and thromboxanes. IL-1 can effect this process by controlling the level of both cyclooxygenase II and inducible nitric oxide synthetase expression (McDaniel *et al.*, 1996, *Proc Soc Exp Biol Med.* 211, 24).

Inhibitors of cytokine production are expected to block inducible cyclooxygenase (COX-2) expression. COX-2 expression has been shown to be increased by cytokines and it is believed to be the isoform of cyclooxygenase responsible for inflammation (M.K. O'Banion *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 1992, 89, 4888.) Accordingly, inhibitors of cytokines such as IL-1 would be expected to exhibit efficacy against those disorders currently treated with COX inhibitors such as the familiar NSAIDs. These disorders include acute and chronic pain as well as symptoms of inflammation and cardiovascular disease.

Elevation of several cytokines have been demonstrated during active inflammatory bowel disease (IBD). A mucosal imbalance of intestinal IL-1 and IL-1ra is present in patients with IBD. Insufficient production of endogenous IL-1ra may contribute to the pathogenesis of IBD (Cominelli, *et al.*, 1996, *Aliment Pharmacol Ther.* 10, 49). Alzheimer disease is characterized by the presence of beta-amyloid protein deposits, neurofibrillary tangles and cholinergic dysfunction throughout the hippocampal region. The structural and metabolic damage found in Alzheimer disease is possibly due to a sustained elevation of IL-1 (Holden, *et al.*, 1995, *Med Hypotheses*, 45, 559). A role for IL-1 in the pathogenesis of human immunodeficiency virus (HIV) has been identified.

IL-1ra showed a clear relationship to acute inflammatory events as well as to the different disease stages in the pathophysiology of HIV infection (Kreuzer, *et al.*, 1997, *Clin Exp Immunol.* 109, 54). IL-1 and TNF are both involved in periodontal disease. The destructive process associated with periodontal disease may be due to a dysregulation of both IL-1 and TNF (Howells, 1995, *Oral Dis.* 1, 266).

Proinflammatory cytokines such as TNF $\alpha$  and IL-1 $\beta$  are also important mediators of septic shock and associated cardiopulmonary dysfunction, acute respiratory distress syndrome (ARDS) and multiple organ failure. In a study of patients presenting at a hospital with sepsis, a correlation was found between TNF $\alpha$  and IL-6 levels and septic complications (Terregino *et al.*, 2000, *Ann. Emerg. Med.*, 35, 26). TNF $\alpha$  has also been implicated in cachexia and muscle degradation, associated with HIV infection (Lahdiverta *et al.*, 1988, *Amer. J. Med.*, 85, 289). Obesity is associated with an increase incidence of infection, diabetes and cardiovascular disease. Abnormalities in TNF $\alpha$  expression have been noted for each of the above conditions (Loffreda, *et al.*, 1998, *FASEB J.* 12, 57). It has been proposed that elevated levels of TNF $\alpha$  are involved in other eating related disorders such as anorexia and bulimia nervosa. Pathophysiological parallels are drawn between anorexia nervosa and cancer cachexia (Holden, *et al.*, 1996, *Med Hypotheses* 47, 423). An inhibitor of TNF $\alpha$  production, HU-211, was shown to improve the outcome of closed brain injury in an experimental model (Shohami, *et al.*, 1997, *J Neuroimmunol.* 72, 169). Atherosclerosis is known to have an inflammatory component and cytokines such as IL-1 and TNF have been suggested to promote the disease. In an animal model an IL-1 receptor antagonist was shown to inhibit fatty streak formation (Elhage *et al.*, 1998, *Circulation*, 97, 242).

TNF $\alpha$  levels are elevated in airways of patients with chronic obstructive pulmonary disease and it may contribute to the pathogenesis of this disease (M.A. Higham *et al.*, 2000, *Eur. Respiratory J.*, 15, 281). Circulating TNF $\alpha$  may also contribute to weight loss associated with this disease (N. Takabatake *et al.*, 2000, *Amer. J. Resp. & Crit. Care Med.*, 161 (4 Pt 1), 1179). Elevated TNF $\alpha$  levels have also been found to be associated with congestive heart failure and the level has been correlated with severity of the disease

(A.M. Feldman *et al.*, 2000, *J. Amer. College of Cardiology*, 35, 537). In addition, TNF $\alpha$  has been implicated in reperfusion injury in lung (Borjesson *et al.*, 2000, *Amer. J. Physiol.*, 278, L3-12), kidney (Lemay *et al.*, 2000, *Transplantation*, 69, 959), and the nervous system (Mitsui *et al.*, 1999, *Brain Res.*, 844, 192).

5

TNF $\alpha$  is also a potent osteoclastogenic agent and is involved in bone resorption and diseases involving bone resorption (Abu-Amer *et al.*, 2000, *J. Biol. Chem.*, 275, 27307). It has also been found highly expressed in chondrocytes of patients with traumatic arthritis (Melchiorri *et al.*, 2000, *Arthritis and Rheumatism*, 41, 2165). TNF $\alpha$  has also been shown to play a key role in the development of glomerulonephritis (Le Hir *et al.*, 1998, *Laboratory Investigation*, 78, 1625).

10

The abnormal expression of inducible nitric oxide synthetase (iNOS) has been associated with hypertension in the spontaneously hypertensive rat (Chou *et al.*, 1998, *Hypertension*, 31, 643). IL-1 has a role in the expression of iNOS and therefore may also have a role in the pathogenesis of hypertension (Singh *et al.*, 1996, *Amer. J. Hypertension*, 9, 867).

15

IL-1 has also been shown to induce uveitis in rats which could be inhibited with IL-1 blockers. (Xuan *et al.*, 1998, *J. Ocular Pharmacol. and Ther.*, 14, 31). Cytokines

20

including IL-1, TNF and GM-CSF have been shown to stimulate proliferation of acute myelogenous leukemia blasts (Bruserud, 1996, *Leukemia Res.* 20, 65). IL-1 was shown to be essential for the development of both irritant and allergic contact dermatitis.

Epicutaneous sensitization can be prevented by the administration of an anti-IL-1 monoclonal antibody before epicutaneous application of an allergen (Muller, *et al.*, 1996, *Am J Contact Dermat.* 7, 177). Data obtained from IL-1 knock out mice indicates the critical involvement in fever for this cytokine (Kluger *et al.*, 1998, *Clin Exp Pharmacol Physiol.* 25, 141). A variety of cytokines including TNF, IL-1, IL-6 and IL-8 initiate the acute-phase reaction which is stereotyped in fever, malaise, myalgia, headaches, cellular hypermetabolism and multiple endocrine and enzyme responses (Beisel, 1995, *Am J Clin Nutr.* 62, 813). The production of these inflammatory cytokines rapidly follows trauma or pathogenic organism invasion.

25

30

Other proinflammatory cytokines have been correlated with a variety of disease states. IL-8 correlates with influx of neutrophils into sites of inflammation or injury. Blocking antibodies against IL-8 have demonstrated a role for IL-8 in the neutrophil associated tissue injury in acute inflammation (Harada *et al.*, 1996, *Molecular Medicine Today* 2, 482). Therefore, an inhibitor of IL-8 production may be useful in the treatment of diseases mediated predominantly by neutrophils such as stroke and myocardial infarction, alone or following thrombolytic therapy, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, hemodialysis, leukopheresis, granulocyte transfusion associated syndromes, and necrotizing enterocolitis.

Rhinovirus triggers the production of various proinflammatory cytokines, predominantly IL-8, which results in symptomatic illnesses such as acute rhinitis (Winther *et al.*, 1998, *Am J Rhinol.* 12, 17).

Other diseases that are effected by IL-8 include myocardial ischemia and reperfusion, inflammatory bowel disease and many others.

The proinflammatory cytokine IL-6 has been implicated with the acute phase response. IL-6 is a growth factor in a number in oncological diseases including multiple myeloma and related plasma cell dyscrasias (Treon, *et al.*, 1998, *Current Opinion in Hematology* 5: 42). It has also been shown to be an important mediator of inflammation within the central nervous system. Elevated levels of IL-6 are found in several neurological disorders including AIDS dementia complex, Alzheimer's disease, multiple sclerosis, systemic lupus erythematosus, CNS trauma and viral and bacterial meningitis (Gruol, *et al.*, 1997, *Molecular Neurobiology* 15: 307). IL-6 also plays a significant role in osteoporosis. In murine models it has been shown to effect bone resorption and to induce osteoclast activity (Ershler *et al.*, 1997, *Development and Comparative Immunol.* 21: 487). Marked cytokine differences, such as IL-6 levels, exist in vivo between osteoclasts of normal bone and bone from patients with Paget's disease (Mills, *et al.*, 1997, *Calcif*

*Tissue Int.* 61, 16). A number of cytokines have been shown to be involved in cancer cachexia. The severity of key parameters of cachexia can be reduced by treatment with anti IL-6 antibodies or with IL-6 receptor antagonists (Strassmann, *et al.*, 1995, *Cytokines Mol Ther.* 1, 107). Several infectious diseases, such as influenza, indicate IL-6 and IFN  
5 alpha as key factors in both symptom formation and in host defense (Hayden, *et al.*, 1998, *J Clin Invest.* 101, 643). Overexpression of IL-6 has been implicated in the pathology of a number of diseases including multiple myeloma, rheumatoid arthritis, Castleman's disease, psoriasis and post-menopausal osteoporosis (Simpson, *et al.*, 1997, *Protein Sci.* 6, 929). Compounds that interfered with the production of cytokines  
10 including IL-6, and TNF were effective in blocking a passive cutaneous anaphylaxis in mice (Scholz *et al.*, 1998, *J. Med. Chem.*, 41, 1050).

GM-CSF is another proinflammatory cytokine with relevance to a number of therapeutic diseases. It influences not only proliferation and differentiation of stem cells but also  
15 regulates several other cells involved in acute and chronic inflammation. Treatment with GM-CSF has been attempted in a number of disease states including burn-wound healing, skin-graft resolution as well as cytostatic and radiotherapy induced mucositis (Masucci, 1996, *Medical Oncology* 13: 149). GM-CSF also appears to play a role in the replication of human immunodeficiency virus (HIV) in cells of macrophage lineage with relevance  
20 to AIDS therapy (Crowe *et al.*, 1997, *Journal of Leukocyte Biology* 62, 41). Bronchial asthma is characterised by an inflammatory process in lungs. Involved cytokines include GM-CSF amongst others (Lee, 1998, *J R Coll Physicians Lond* 32, 56).

Interferon  $\gamma$  (IFN  $\gamma$ ) has been implicated in a number of diseases. It has been associated  
25 with increased collagen deposition that is a central histopathological feature of graft-versus-host disease (Parkman, 1998, *Curr Opin Hematol.* 5, 22). Following kidney transplantation, a patient was diagnosed with acute myelogenous leukemia.

Retrospective analysis of peripheral blood cytokines revealed elevated levels of GM-CSF and IFN  $\gamma$ . These elevated levels coincided with a rise in peripheral blood white cell  
30 count (Burke, *et al.*, 1995, *Leuk Lymphoma.* 19, 173). The development of insulin-dependent diabetes (Type 1) can be correlated with the accumulation in pancreatic islet

cells of T-cells producing IFN  $\gamma$  (Ablumunits, *et al.*, 1998, *J Autoimmun.* 11, 73). IFN  $\gamma$  along with TNF, IL-2 and IL-6 lead to the activation of most peripheral T-cells prior to the development of lesions in the central nervous system for diseases such as multiple sclerosis (MS) and AIDS dementia complex (Martino *et al.*, 1998, *Ann Neurol.* 43, 340).

5 Atherosclerotic lesions result in arterial disease that can lead to cardiac and cerebral infarction. Many activated immune cells are present in these lesions, mainly T-cells and macrophages. These cells produce large amounts of proinflammatory cytokines such as TNF, IL-1 and IFN  $\gamma$ . These cytokines are thought to be involved in promoting apoptosis or programmed cell death of the surrounding vascular smooth muscle cells resulting in

10 the atherosclerotic lesions (Geng, 1997, *Heart Vessels Suppl* 12, 76). Allergic subjects produce mRNA specific for IFN  $\gamma$  following challenge with *Vespula* venom (Bonay, *et al.*, 1997, *Clin Exp Immunol.* 109, 342). The expression of a number of cytokines, including IFN  $\gamma$  has been shown to increase following a delayed type hypersensitivity reaction thus indicating a role for IFN  $\gamma$  in atopic dermatitis (Szepietowski, *et al.*, 1997,

15 *Br J Dermatol.* 137, 195). Histopathologic and immunohistologic studies were performed in cases of fatal cerebral malaria. Evidence for elevated IFN  $\gamma$  amongst other cytokines was observed indicating a role in this disease (Udomsangpetch *et al.*, 1997, *Am J Trop Med Hyg.* 57, 501). The importance of free radical species in the pathogenesis of various infectious diseases has been established. The nitric oxide synthesis pathway is

20 activated in response to infection with certain viruses via the induction of proinflammatory cytokines such as IFN  $\gamma$  (Akaike, *et al.*, 1998, *Proc Soc Exp Biol Med.* 217, 64). Patients, chronically infected with hepatitis B virus (HBV) can develop cirrhosis and hepatocellular carcinoma. Viral gene expression and replication in HBV transgenic mice can be suppressed by a post-transcriptional mechanism mediated by IFN

25  $\gamma$ , TNF and IL-2 (Chisari, *et al.*, 1995, *Springer Semin Immunopathol.* 17, 261). IFN  $\gamma$  can selectively inhibit cytokine induced bone resorption. It appears to do this via the intermediacy of nitric oxide (NO) which is an important regulatory molecule in bone remodeling. NO may be involved as a mediator of bone disease for such diseases as: the rheumatoid arthritis, tumor associated osteolysis and postmenopausal osteoporosis

30 (Evans, *et al.*, 1996, *J Bone Miner Res.* 11, 300). Studies with gene deficient mice have demonstrated that the IL-12 dependent production of IFN  $\gamma$  is critical in the control of

early parasitic growth. Although this process is independent of nitric oxide the control of chronic infection does appear to be NO dependent (Alexander *et al.*, 1997, *Philos Trans R Soc Lond B Biol Sci* 352, 1355). NO is an important vasodilator and convincing evidence exists for its role in cardiovascular shock (Kilbourn, *et al.*, 1997, *Dis Mon.* 43, 277). IFN  $\gamma$  is required for progression of chronic intestinal inflammation in such diseases as Crohn's disease and inflammatory bowel disease (IBD) presumably through the intermediacy of CD4<sup>+</sup> lymphocytes probably of the TH1 phenotype (Sartor 1996, *Aliment Pharmacol Ther.* 10 Suppl 2, 43). An elevated level of serum IgE is associated with various atopic diseases such as bronchial asthma and atopic dermatitis. The level of IFN  $\gamma$  was negatively correlated with serum IgE suggesting a role for IFN  $\gamma$  in atopic patients (Teramoto *et al.*, 1998, *Clin Exp Allergy* 28, 74).

WO 01/01986 discloses particular compounds alleged to having the ability to inhibit TNF- $\alpha$ . The specific inhibitors disclosed are structurally distinct from the novel compounds disclosed in the present application disclosed hereinbelow. Certain compounds disclosed in WO 01/01986 are indicated to be effective in treating the following diseases: dementia associated with HIV infection, glaucoma, optic-neuropathy, optic neuritis, retinal ischemia, laser induced optic damage, surgery or trauma-induced proliferative vitreoretinopathy, cerebral ischemia, hypoxia-ischemia, hypoglycemia, domoic acid poisoning, anoxia, carbon monoxide or manganese or cyanide poisoning, Huntington's disease, Alzheimer's disease, Parkinson's disease, meningitis, multiple sclerosis and other demyelinating diseases, amyotrophic lateral sclerosis, head and spinal cord trauma, seizures, convulsions, olivopontocerebellar atrophy, neuropathic pain syndromes, diabetic neuropathy, HIV-related neuropathy, MERRF and MELAS syndromes, Leber's disease, Wernicke's encephalopathy, Rett syndrome, homocystinuria, hyperprolinemia, hyperhomocysteinemia, nonketotic hyperglycinemia, hydroxybutyric aminoaciduria, sulfite oxidase deficiency, combined systems disease, lead encephalopathy, Tourett's syndrome, hepatic encephalopathy, drug addiction, drug tolerance, drug dependency, depression, anxiety and schizophrenia.

Compounds which modulate release of one or more of the aforementioned inflammatory cytokines can be useful in treating diseases associated with release of these cytokines. For example, WO 98/52558 discloses heteroaryl urea compounds which are indicated to be useful in treating cytokine mediated diseases. WO 99/23091 discloses another class of urea compounds which are useful as anti-inflammatory agents. WO 99/32463 relates to aryl ureas and their use in treating cytokine diseases and proteolytic enzyme mediated disease. WO 00/41698 discloses aryl ureas said to be useful in treating p38 MAP kinase diseases.

U.S. Pat. No. 5,162,360 discloses N-substituted aryl-N'-heterocyclic substituted urea compounds which are described as being useful for treating hypercholesterolemia and atherosclerosis.

The work cited above supports the principle that inhibition of cytokine production will be beneficial in the treatment of various disease states. Some protein therapeutics are in late development or have been approved for use in particular diseases. Protein therapeutics are costly to produce and have bioavailability and stability problems. Therefore a need exists for new small molecule inhibitors of cytokine production with optimized efficacy, pharmacokinetic and safety profiles.

#### BRIEF SUMMARY OF THE INVENTION

The work cited above supports the principle that inhibition of cytokine production will be beneficial in the treatment of various disease states.

It is therefore an object of the invention to provide novel compounds which inhibit the release of inflammatory cytokines such as interleukin-1 and tumor necrosis factor.

It is a further object of the invention to provide methods for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease, using the novel compounds of the invention.


It is yet a further object of the invention to provide processes of preparation of the above-mentioned novel compounds.

5


### DETAILED DESCRIPTION OF THE INVENTION

In a first embodiment, the invention provides the following compounds:


10




1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-isopropyl-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;




1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2,6-dimethyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;




1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;




1-(5-tert-Butyl-2-methoxy-3-[1,2,4]triazol-4-yl-phenyl)-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;













1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-oxo-2H-pyran-4-yloxy)-naphthalen-1-yl]-urea;























5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-benzoic acid;











Carbonic acid 5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl ester methyl ester;












or the pharmaceutically acceptable derivatives thereof.

- 5 In a second embodiment, the invention provides the following compounds:







N-(3-{3-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide;




N-(3-{3-[4-(2-Amino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide;




N-(5-tert-Butyl-3-{3-[4-(2-cyano-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-2-methoxy-phenyl)-methanesulfonamide;




N-(5-tert-Butyl-2-methoxy-3-{3-[4-(tetrahydropyran-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide




N-(5-tert-Butyl-2-methoxy-3-{3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;




N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;




N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-methyl-2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;




N-[5-tert-Butyl-3-(3-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-2-methoxy-phenyl]-methanesulfonamide;



N-[5-tert-Butyl-3-(3-{4-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-2-methoxy-phenyl]-methanesulfonamide;



N-{5-tert-Butyl-2-methoxy-3-[3-(4-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-ureido]-phenyl}-methanesulfonamide;




N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-pyrrolidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;


or the pharmaceutically acceptable derivatives thereof.

In a third embodiment, the invention provides the following compounds:


5




1-[5-tert-butyl-2-(2-hydroxy-4-methyl-phenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea;



1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-{4-[2-(hydroxy)ethoxy]-naphthalen-1-yl}-urea;



1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-{4-[2-oxo-2-(morpholin-4-yl)-ethoxy]-naphthalen-1-yl}-urea;




1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-{4-[hydroxy]-naphthalen-1-yl}-urea











or the pharmaceutically acceptable derivatives thereof.


In a fourth embodiment, the invention provides the following compounds which can be made by the procedures illustrated in the General Synthetic Methods and Experimental sections provided herein below:


10




1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-isopropylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;









1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(2-dimethylamino-ethyl)-methyl-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;




1-[4-(2-Benzylamino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea;




1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-methyl-2-(1-phenyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;




1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-methyl-2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;




1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-dimethylamino-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;




1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-methyl-2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;




1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-dimethylamino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;




N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;




N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(1-phenyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;




N-[5-tert-Butyl-2-methoxy-3-(3-{4-[6-methyl-2-(1-phenyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;




N-{5-tert-Butyl-2-methoxy-3-[3-(4-{2-[(pyridin-3-yl)methyl]-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-ureido]-phenyl}-methanesulfonamide;




N-[5-tert-Butyl-3-(3-{4-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-2-methoxy-phenyl]-methanesulfonamide;




N-[5-tert-Butyl-3-(3-{4-[2-(2-dimethylamino-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-2-methoxy-phenyl]-methanesulfonamide;




N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;




N-[5-tert-Butyl-2-methoxy-3-(3-{4-[6-methyl-2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;




N-(5-tert-Butyl-3-{3-[4-(2-dimethylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-2-methoxy-phenyl)-methanesulfonamide;




N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;













N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-piperidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido)-phenyl)-methanesulfonamide;




N-{5-tert-Butyl-3-[3-(4-{2-[(2-dimethylamino-ethyl)-methyl-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-ureido]-2-methoxy-phenyl}-methanesulfonamide;




N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(tetrahydrofuran-3-ylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;







2-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylcarbamoyl-pyridin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;




2-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylamino-pyridin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;




1-{5-tert-Butyl-2-methoxy-3-[4-(pyrrolidine-1-carbonyl)-thiazol-2-ylamino]-phenyl}-3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-urea;




1-[5-tert-Butyl-2-methoxy-3-(4-pyrrolidin-1-ylmethyl-thiazol-2-ylamino)-phenyl]-3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-urea;




2-(5-tert-Butyl-2-methoxy-3-{3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;




2-(3-{3-[4-(2-Amino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-5-tert-butyl-2-methoxy-phenylamino)-thiazole-4-carboxylic acid ethyl ester;




2-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;




2-[5-tert-Butyl-3-(3-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-2-methoxy-phenylamino]-thiazole-4-carboxylic acid ethyl ester;




2-(5-tert-Butyl-2-methoxy-3-{3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide;




1-{5-tert-Butyl-2-methoxy-3-[4-(pyrrolidine-1-carbonyl)-thiazol-2-ylamino]-phenyl}-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;




1-[5-tert-Butyl-2-methoxy-3-(4-pyrrolidin-1-ylmethyl-thiazol-2-ylamino)-phenyl]-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;




1-[5-tert-Butyl-2-methoxy-3-(4-pyrrolidin-1-ylmethyl-thiazol-2-ylamino)-phenyl]-3-[4-(2-isopropylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;




1-[5-tert-Butyl-2-methoxy-3-[4-(pyrrolidine-1-carbonyl)-thiazol-2-ylamino]-phenyl]-3-[4-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl]-urea;




1-[5-tert-Butyl-2-methoxy-3-(4-pyrrolidin-1-ylmethyl-thiazol-2-ylamino)-phenyl]-3-[4-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl]-urea;




1-[5-tert-Butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-urea;




1-[5-tert-Butyl-3-(3-dimethylaminomethyl)-2-methoxy-phenyl]-3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-urea;




1-[5-tert-Butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-3-[4-(2-dimethylaminomethyl-pyridin-4-yloxy)-naphthalen-1-yl]-urea;












1-[5-tert-Butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;



1-[4-(2-Amino-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-[5-tert-butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-urea;



1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-[5-tert-butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-urea;



or the pharmaceutically acceptable derivatives thereof.

In all the compounds disclosed above, in the event the nomenclature is in conflict with the structure, it shall be understood that the compound is defined by the structure.

Any compounds of this invention containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be in the R or S

5 configuration, or a combination of configurations.

Some of the compounds of the invention can exist in more than one tautomeric form. The invention includes all such tautomers. It shall also be understood that the invention includes all homologs, analogs, optical and positional isomers thereof.

10 All terms as used herein in this specification, unless otherwise stated, shall be understood in their ordinary meaning as known in the art.

Any of the aromatic ring systems, carbocyclic or heterocyclic, shall be understood to  
15 include the non-aromatic ring systems which may be mono- or polyunsaturated, and the positional isomers or analogs thereof.

Any of the compounds described hereinabove possessing "nitrogen" and "sulfur" shall include any oxidized form of nitrogen and sulfur and the quaternized form of any basic  
20 nitrogen.

The compounds of the invention are only those which are contemplated to be 'chemically stable' as will be appreciated by those skilled in the art. For example, a compound which would have a 'dangling valency', or a 'carbanion' are not compounds contemplated by  
25 the invention.

The invention includes pharmaceutically acceptable derivatives of the novel compounds disclosed herein. A "pharmaceutically acceptable derivative" refers to any pharmaceutically acceptable salt or ester of a compound of this invention, or any other  
30 compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound of this invention, a pharmacologically active metabolite or

pharmacologically active residue thereof. A pharmacologically active metabolite shall be understood to mean any of the novel compounds disclosed herein capable of being metabolized enzymatically or chemically. This includes, for example, hydroxylated or oxidized derivative compounds.

5

Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfuric, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfuric and benzenesulfonic acids. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of this invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(C<sub>1</sub>-C<sub>4</sub> alkyl)<sub>4</sub><sup>+</sup> salts.

10

15

20

25

In addition, the compounds of this invention include prodrugs of compounds of the the novel compounds disclosed herein. Prodrugs include those compounds that, upon simple chemical transformation, are modified to produce compounds of the invention. Simple chemical transformations include hydrolysis, oxidation and reduction. Specifically, when a prodrug of this invention is administered to a patient, the prodrug may be transformed into a novel compound of the invention, thereby imparting the desired pharmacological effect.

### METHODS OF USE

30

In accordance with the invention, there are provided methods of using the compounds of the invention. The compounds of the invention effectively block inflammatory cytokine production from cells. The inhibition of cytokine production is an attractive means for

preventing and treating a variety of cytokine mediated diseases or conditions associated with excess cytokine production, *e.g.*, diseases and pathological conditions involving inflammation. Thus, the compounds of the invention are useful for the treatment of such conditions. These encompass diseases including, but not limited to, rheumatoid arthritis, osteoarthritis, traumatic arthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, systemic lupus erythematosus, glomerulonephritis, reperfusion injury, sepsis, bone resorption diseases including osteoporosis, chronic obstructive pulmonary disease, congestive heart failure, Alzheimer's disease, atherosclerosis, toxic shock syndrome, asthma, contact dermatitis, percutaneous transluminal coronary angioplasty (PTCA) and insulin-dependent diabetes mellitus.

In addition, the compounds of the invention being inhibitors of cytokine production are expected to block inducible cyclooxygenase (COX-2) expression. COX-2 expression has been shown to be increased by cytokines and it is believed to be the isoform of cyclooxygenase responsible for inflammation (M.K. O'Banion *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 1992, 89, 4888.) Accordingly, the present novel compounds would be expected to exhibit efficacy against those disorders currently treated with COX inhibitors such as the familiar NSAIDs. These disorders include acute and chronic pain as well as symptoms of inflammation and cardiovascular disease.

As discussed in the Background of the Invention, IL-8 plays a role in the influx of neutrophils into sites of inflammation or injury. Therefore, in a yet further aspect of the invention, the compounds of the invention may be useful in the treatment of diseases mediated predominantly by neutrophils such as stroke and myocardial infarction, alone or following thrombolytic therapy, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, acute glomerulonephritis, dermatoses with acute inflammatory components, acute purulent meningitis or other central nervous system disorders, hemodialysis, leukopheresis, granulocyte transfusion associated syndromes, and necrotizing enterocolitis.

For therapeutic use, the compounds of the invention may be administered in any conventional dosage form in any conventional manner. Routes of administration include, but are not limited to, intravenously, intramuscularly, subcutaneously, intrasynovially, by infusion, sublingually, transdermally, orally, topically or by inhalation. The preferred  
5 modes of administration are oral and intravenous.

The compounds of this invention may be administered alone or in combination with adjuvants that enhance stability of the inhibitors, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or  
10 dispersion, increase inhibitory activity, provide adjunct therapy, and the like, including other active ingredients. Advantageously, such combination therapies utilize lower dosages of the conventional therapeutics, thus avoiding possible toxicity and adverse side effects incurred when those agents are used as monotherapies. Compounds of the invention may be physically combined with the conventional therapeutics or other  
15 adjuvants into a single pharmaceutical composition. Advantageously, the compounds may then be administered together in a single dosage form. In some embodiments, the pharmaceutical compositions comprising such combinations of compounds contain at least about 5%, but more preferably at least about 20%, of a compound of the invention (w/w) or a combination thereof. The optimum percentage (w/w) of a compound of the  
20 invention may vary and is within the purview of those skilled in the art. Alternatively, the compounds may be administered separately (either serially or in parallel). Separate dosing allows for greater flexibility in the dosing regime.

As mentioned above, dosage forms of the compounds of this invention include  
25 pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art. These carriers and adjuvants include, for example, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes and cellulose-based substances. Preferred dosage forms include, tablet, capsule, caplet, liquid, solution, suspension, emulsion, lozenges, syrup, reconstitutable powder, granule,  
30 suppository and transdermal patch. Methods for preparing such dosage forms are known (see, for example, H.C. Ansel and N.G. Popovich, *Pharmaceutical Dosage Forms and*

*Drug Delivery Systems*, 5th ed., Lea and Febiger (1990)). Dosage levels and requirements are well-recognized in the art and may be selected by those of ordinary skill in the art from available methods and techniques suitable for a particular patient. In some embodiments, dosage levels range from about 1-1000 mg/dose for a 70 kg patient.

- 5 Although one dose per day may be sufficient, up to 5 doses per day may be given. For oral doses, up to 2000 mg/day may be required. As the skilled artisan will appreciate, lower or higher doses may be required depending on particular factors. For instance, specific dosage and treatment regimens will depend on factors such as the patient's general health profile, the severity and course of the patient's disorder or disposition  
10 thereto, and the judgment of the treating physician.

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustrating preferred embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way.


- 15 The examples which follow are illustrative and, as recognized by one skilled in the art, particular reagents or conditions could be modified as needed for individual compounds without undue experimentation. Starting materials used in the scheme below are either commercially available or easily prepared from commercially available materials by those skilled in the art.

20

#### GENERAL SYNTHETIC METHODS

- The invention additionally provides for methods of making the compounds of the the invention. The compounds of the invention and intermediates used in their preparation  
25 may be prepared by the general methods and examples presented below, and methods known to those of ordinary skill in the art. Further reference in this regard may be made to the general methods and examples found in US patent. nos. 6,319,921 and 6,358,945, US application nos. 09/714,539, 09/611,109, 09/698,442, 09/834,797 and 09/902,085, and US provisional application no. 60/283,642. Each of the aforementioned are  
30 incorporated herein by reference in their entirety. In all schemes "L" in the formulas


shown below shall be defined as moieties on the left side of the urea bond, "R" shall be understood to mean all possible moieties on the right side of the urea bond. For example, the left side 'L' and the right side 'R' of the compound




5 respectively.

The compounds of the invention may be prepared by Method A, B, C or D as illustrated in Scheme I, preferably Method C.


Scheme I

**Method A**


(or a precursor)

**Method B**

(or a precursor)

**Method C**

(or a precursor)

**Method D**

(or a precursor)

In Method A, a mixture of an arylamine of formula IIa and an arylisocyanate of formula III is dissolved in a non-protic, anhydrous solvent such as THF, ether, toluene, dioxane or ethyl acetate. The preferred solvent is THF. The mixture is stirred at between 0 - 45° C, preferably at 25° C, for 2-24 h, and the volatiles are removed. Purification of the residue can be accomplished by recrystallization from an appropriate solvent such as ethyl acetate/hexanes, ethyl acetate/methanol, THF/petroleum ether or ethanol/water or by silica gel chromatography, using for example, hexanes and ethyl acetate as eluents, providing the product compound or precursors thereof.

In Method B, an arylamine of formula IIa is dissolved in a halogenated solvent, such as methylene chloride, chloroform or dichloroethane. The preferred solvent is methylene chloride. The mixture is diluted with aqueous alkali, such as sodium bicarbonate or potassium carbonate, cooled in an ice bath and phosgene is added. The mixture is  
5 vigorously stirred for 5 – 30 min, with 10 min being preferable. The organic layer is dried, with agents such as  $\text{MgSO}_4$  or  $\text{Na}_2\text{SO}_4$ , and the volatiles removed to provide the corresponding isocyanate. The isocyanate and arylamine IV are mixed in a non-protic, anhydrous solvent such as THF, ether, toluene, dioxane, methylene chloride or ethyl acetate. The preferred solvent is THF. The mixture is stirred at between 0 - 45° C,  
10 preferably at 25° C, for 2 - 24 h, and the volatiles are removed. Purification of the residue by recrystallization or by silica gel chromatography, as above, provides the product compound or precursors thereof.

In Method C, an arylamine of formula IIa is dissolved in a suitable halogenated solvent such as methylene chloride, chloroform or dichloroethane. The preferred solvent is  
15 methylene chloride. A suitable base such as triethylamine may be added, followed by an alkyl or aryl chloroformate, such as *t*-butyl chloroformate or phenyl chloroformate (shown). The mixture is stirred at between 0 - 85° C, preferably at reflux temperature, for 2 - 24 h, and the volatiles are removed providing carbamate V. The carbamate and arylamine IV are mixed in a non-protic, anhydrous solvent such as THF, ether, toluene,  
20 dioxane, methylene chloride or ethyl acetate. The preferred solvent is THF. The mixture is stirred at between 0 - 110 °C, preferably at reflux temperature, for 2 - 24 h, and the volatiles are removed. Purification of the residue as above provides the product compound or precursors thereof.

25 In Method D, an aromatic carboxylic acid (IIb) is dissolved in a non-protic solvent, such as THF or diethyl ether, and an inorganic base, such as triethyl amine is added and the mixture is cooled to -30-0°C, with the preferred temperature being -10°C. An alkyl chloroformate, such as ethyl chloroformate, is added dropwise and the resulting mixture stirred at below room temperature, such as 0°C for 1-3 hours. A solution of sodium azide

in water is added and the mixture stirred between 1-3 hours, diluted with toluene and the organic layer dried and reduced in volume. This mixture is heated at reflux for 1-4 hours, cooled to room temperature to give isocyanate (Va) which can be reacted with amine (IV) to give the product compound or precursors thereof.


5

### EXPERIMENTAL SECTION

Amine intermediates of formula IIa are either commercially available or may be prepared by methods known to those skilled in the art. Examples 1-4 are representative of procedures for preparing aryl amine or aryl isocyanate derivatives that may be used in Methods A-D. It will be apparent to those skilled in the art that other desired intermediates could be made by these methods by using appropriately substituted starting materials and intermediates.

15

#### **Example 1: Synthesis of 1-(5-tert-butyl-2-methoxy-phenyl)-3-[4-(2-cyano-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea**




- 20 To a 0 °C solution of trimethyl amine (20% solution in water, 3.8 mmol) in 2 mL of dimethylformamide was added 4-(2-chloro-pyrimidin-4-yloxy)-naphthalen-1-ylamine (270 mg, 1 mmol). The deep tan solution was warmed to room temperature for 3 h, during which the initially light suspension became a brown suspension. After this time, tetraethylammonium cyanide (156 mg, 1 mmol) was added all at once to provide a deep

amber solution. After 1 h, the reaction was quenched with water, extracted with EtOAc and dried over magnesium sulfate. Column chromatography (10-60% EtOAc-hexanes) provided 142 mg (54%) of 4-(4-amino-naphthalen-1-yloxy)-pyrimidine-2-carbonitrile.

- 5 To a 0 °C biphasic solution of the above nitrile (47 mg, 0.18 mmol) was added 0.3 mL (2.6 mmol) of phosgene. The solution was stirred for 15 min at 0 °C, then warmed to room temperature for 1 h. After this time, the reaction was extracted, dried over MgSO<sub>4</sub> and concentrated in vacuo. The resulting orange solid was added to a solution of *tert*-butyl anisidine (75 mg, 0.35 mmol). The reaction was stirred overnight, concentrated in  
10 vacuo, and triturated with 3:1 hexanes: EtOAc to provide 55 mg (69%) of the title compound as an off-white solid.

**Example 2: Synthesis of N-(5-*tert*-butyl-2-methoxy-3-{3-[4-(tetrahydro-pyran-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide**



- 20 Triphenylphosphine (2.8 g, 10.8 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. To this colorless solution diethylazodicarboxylate (1.9 grams, 10.8 mmol) was added dropwise to afford an orange solution. After 15 min at 0 °C, a copious precipitate had formed. 4-Hydroxy-naphthalen-1-yl-carbamic acid *tert*-butyl ester (934 mg, 3.6 mmol) and tetrahydro-4*H*-pyran-4-ol (552 mg, 5.4 mmol) were then added in one portion as a

solution in 2 mL of THF. The purple suspension was stirred at 0 °C for one h then at room temperature for 48 h. The solvent was then evaporated and chromatographed on silica gel (40% EtOAc-hexanes) to provide 680 mg (55%) of [4-(tetrahydro-pyran-4-yloxy)-naphthalen-1-yl]-carbamic acid tert-butyl ester as a purple solid.

5

The above tert-butyl ester (680 mg, 1.98 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and to the purple solution was added trifluoroacetic acid (1.14 g, 10 mmol) and the reaction was stirred overnight at room temperature. The reaction was then diluted with CH<sub>2</sub>Cl<sub>2</sub> (50 mL) and washed with 50% saturated aqueous NaHCO<sub>3</sub> (50 mL). The organic portion was then washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo provide 460 mg (95%) of 4-(tetrahydro-pyran-4-yloxy)-naphthalen-1-ylamine as a purple solid.


10

15

The title compound was prepared from the above amine and N-(3-amino-5-tert-butyl-2-methoxyphenyl)methanesulfonamide by the procedure described for 1-(5-tert-butyl-2-methoxy-phenyl)-3-[4-(2-cyano-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea (Example 1).

20

**Example 3: Synthesis of 4-{4-[3-(5-tert-butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidine-2-carboxylic acid methyl ester**




To a solution of [4-(2-iodo-pyrimidin-4-yloxy)-naphthalen-1-yl]-carbamic acid tert-butyl ester (100 mg, 0.44 mmol) in 2 mL of DMF, was added, 0.5 mL MeOH, 0.12 mL of  $\text{Et}_3\text{N}$  (0.9 mmol),  $\text{Pd}(\text{OAc})_2$  (10 mg, 0.04 mmol), and DPPF (44 mg, 0.4 mmol). The reaction was heated under a CO balloon at 60 °C for 5 h. The reaction was then diluted with EtOAc, concentrated in vacuo on silica gel and chromatographed directly with 10-80% EtOAc-hexanes to provide 26 mg (14%) of 4-(4-tert-butoxycarbonylamino-naphthalen-1-yloxy)-pyrimidine-2-carboxylic acid methyl ester as a brown solid.

To a solution of the above methyl ester (176 mg, 0.47 mmol) was added 5 mL of TFA. After 2 h, the reaction was concentrated in vacuo. The brown solid was suspended in toluene and concentrated in vacuo two more times. Ether trituration provided 94 mg (74%) of 4-(4-amino-naphthalen-1-yloxy)-pyrimidine-2-carboxylic acid methyl ester as a brown solid, which is used without further purification.

The title compound was prepared from the above amine and 5-tert-butyl-2-methoxyaniline by the procedure described for 1-(5-tert-butyl-2-methoxy-phenyl)-3-[4-(2-cyano-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea (Example 1).

**Example 4: Synthesis of 1-(2-methoxy-5-trimethylsilanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea**

5



To a  $-30\text{ }^\circ\text{C}$  solution of 4-methoxyphenyl trimethyl silane prepared from 4-bromoanisole via the procedure of Ellman *et al.* (*J. Org. Chem.* **1997**, 62, 6102) (1.5 g, 8.3 mmol) was added  $\text{NO}_2\text{BF}_4$  (1.1 g, 8.4 mmol) in  $\text{CH}_3\text{CN}$ . The resulting deep brown solution was stirred for 20 min, then water was added and the reaction was extracted with  $\text{EtOAc}$ , dried over  $\text{MgSO}_4$  and concentrated in vacuo. The crude material was chromatographed on silica gel (25%  $\text{EtOAc}$ -hexanes) to provide 760 mg (40%) of (4-methoxy-3-nitrophenyl)-trimethyl-silane as a gold oil.

15


The above trimethyl-silane (760 mg, 3.4 mmol) was dissolved in 25 mL of  $\text{EtOH}$ . To this was added 10%  $\text{Pd/C}$  (128 mg). The reaction was stirred for 12 h under a 1 atm balloon of hydrogen gas. The reaction was then filtered through diatomaceous earth and concentrated in vacuo to provide 400 mg (60%) of 2-methoxy-5-trimethylsilanyl-phenylamine as an amber oil which was used without further purification.

20

The title compound was prepared from the above amine and 4-[5-(4-aminonaphthyl)pyridin-2-ylmethyl]morpholine by the procedure described for 1-(5-tert-butyl-2-methoxy-phenyl)-3-[4-(2-cyano-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea


(Example 1).

**Example 5: Synthesis of 1-(5-tert-butyl-2-methoxy-phenyl)-3-[4-(2-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea**



1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-chloro-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea (50 mg, 0.1 mmol) was dissolved in 0.4 mL of DMF. To this was added PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (10 mol%), o-methoxyboronic acid (32 mg, 0.2 mmol) in 2 mL of DME/H<sub>2</sub>O/EtOH (7:3:2) and 0.53 mL of Na<sub>2</sub>CO<sub>3</sub> (2M). The reaction was heated in a Smith synthesizer microwave for 3 min at 160 °C. The product was concentrated on silica and purified (15-30% EtOAc-hexanes) to provide 13 mg (23%) of the title compound as an off-white foam.

**Example 6: Synthesis of 2-(5-tert-butyl-2-methoxy-3-{3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester**




To a solution of N-(5-tert-butyl-2-methoxy-3-nitrophenyl) thiourea (1.0g, 3.55 mmol) in EtOH (20 mL) was added bromoethylpyruvate (727 mg, 3.73 mmol). This solution was heated to reflux for 12h. The TLC showed consumption of all starting thiourea and formation of one new product spot. The solvent was removed under vacuum and the resulting solid triturated by a mixture of hexane/EtOAc (2:1) to get the desired thiazole product as a yellow solid (1.2 g, 86% yield).

To a solution of the above thiazole (1 g, 2.66 mmol) in a mixture of THF/EtOAc (1:1, 60 mL) palladium on carbon (10%, 200 mg) was added in one portion. The black yellow suspension was subjected to hydrogen pressure (50 psi) for 16 h. The catalyst was removed by filtration through diatomaceous earth, and the resulting solution was concentrated to give the desired aniline intermediate as a thick, brown oil.

To a solution of the above aniline (100 mg, 0.29mmol) in dichloromethane (2 mL) was added a preformed solution of 4-(pyridin-4-yloxy)-naphthalen-1-yl isocyanate (250 mg, 0.86 mmol) in dichloromethane 2mL. This solution was stirred at room temperature for 12 h. The solvent was removed by rotary evaporation and the resulting oil purified on a flash silica gel column eluting with a dichloromethane-MeOH mixture (95:5) to provide the title compound as light brown foam (50 mg, 29% yield).

**Example 7: Synthesis of 1-(5-tert-butyl-2-methoxy-phenyl)-3-[4-(2-isopropyl-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea**



Boron trifluoride etherate (4.0 mL, 31.1 mmol, 1.5 equiv.) was cooled on an ice bath under inert atmosphere in a dry round bottom flask. 4-Amino-1-nitronaphthalene (3.9 g, 20.7 mmol, 1 equiv.) dissolved in 100 mL anhydrous DME was added slowly, over 10 min. After stirring 15 min, tert-butyl nitrite (3.0 mL, 24.8 mmol, 1.2 equiv.) was added dropwise via syringe. The ice bath was removed and the mixture was stirred at room temperature for 1.5 h. A precipitate of golden green color had formed. The mixture was then re-cooled to  $0\text{ }^\circ\text{C}$  and the precipitated 4-nitro-naphthalene diazonium tetrafluoroborate salt 5.1 g (17.7 mmol or 86 %) was collected via vacuum filtration through a Buchner funnel.

The diazonium salt from above (408 mg, 1.42 mmol, 1 equiv.) was mixed with silica gel (63-200 micron, 2500 mg) and rendered homogeneous by light mixing in a mortar. This mixture was placed in a round bottom flask equipped with a mechanical stirrer and a condenser, and heated to  $150\text{--}170\text{ }^\circ\text{C}$  for 0.5 h. The mixture turned dark. The solid mixture was allowed to cool back to room temperature, placed on top of a short plug of silica gel, the transfer being aided by some hexanes solvent. The pure 4-fluoro-1-nitronaphthalene product was eluted with 10% EtOAc in hexanes. After removal of the

solvents in vacuo 190 mg of product (0.99 mmol, 70% yield) was collected as a yellow-orange solid.


2-Isopropyl-6-methyl-4-pyrimidinol ( 264 mg, 1.74 mmol, 1.1 equiv.) was dissolved in 2.5 mL anhydrous DMSO. Sodium tert-butoxide ( 159 mg, 1.66 mmol, 1.05 equiv.) was added in one portion and the mixture was left stirring for 15 min at room temperature. Solid 4-fluoro-1-nitro-naphthalene was then added in one portion and the mixture was gently heated to 60 °C while stirring for 4 h. A color change from orange to green was noted. Saturated aqueous sodium bicarbonate solution was then added and the product extracted 3 times with EtOAc. The combined organic extracts were washed once with water and with brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and filtered. The volatiles were removed in vacuo to afford a waxy orange solid. Crude yield was 459 mg (1.42 mmol or 90%). The material was used without purification for the next step.

The crude nitronaphthyl-pyrimidinyl ether from above (459 mg, 1.42 mmol, 1 equiv.) was taken up in 35 mL EtOAc and 35 mL EtOH. Ammonium formate was added (537 mg, 8.52 mmol, 6 equiv.) as well as 400 mg of 10% palladium-on-carbon. The reaction mixture was heated to a gentle reflux for one h, cooled back to room temperature, filtered through diatomaceous earth and the volatiles were removed in vacuo. The crude product was purified by chromatography on SiO<sub>2</sub>, eluting with 20-40% EtOAc in hexanes. The desired aminonaphthyl-pyrimidinyl ether was isolated as a yellow foam (176 mg, 0.6 mmol, 42 % for 2 steps).

5-tert-Butyl-ortho-anisidine ( 107 mg, 0.60 mmol, 1 equiv.) was dissolved in 25 mL dichloromethane and 20 mL saturated aqueous sodium bicarbonate solution was added. The mixture was cooled to 0 °C. Without stirring, phosgene (2.0 M in toluene, 1.05 mL, 2.1 mmol, 3.5 equiv.) was added in one portion to the organic layer via syringe. After 15 min the layers were separated and the aqueous phase was extracted with one portion of dichloromethane. The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and the majority of the solvent was removed in vacuo. To this isocyanate residue was immediately added a solution of the naphthylamino-pyrimidinyl ether from above (88 mg, 0.3 mmol, 0.5

equiv.) in 2.5 mL anhydrous THF. The mixture was left stirring at room temperature overnight, then MeOH was added and the solvents removed in vacuo. A purple foam was obtained, which was purified by column chromatography on SiO<sub>2</sub>, eluting with 0-10 % MeOH in dichloromethane. Recrystallization from acetonitrile/water afforded 76 mg of the title compound as a white solid (0.15 mmol, 50 % yield).


**Example 8: Synthesis of N-(3-{3-[4-(2-isopropyl-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide**



The intermediate naphthylamino-pyrimidinyl ether from Example 7 (104 mg, 0.36 mmol, 1 equiv.) was dissolved in 20 mL dichloromethane and 20 mL saturated aqueous sodium bicarbonate solution was added. The mixture was cooled to 0 °C. Without stirring, phosgene (2.0 M in toluene, 0.62 mL, 1.24 mmol, 3.5 equiv.) was added in one portion to the organic layer via syringe. After 15 min the layers were separated and the aqueous phase was extracted with one portion of dichloromethane. The combined organics were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered and the majority of the solvent was removed in vacuo. To this isocyanate residue was immediately added a solution of N-(3-amino-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide (97 mg, 0.36 mmol, 1 equiv.) in 2.5 mL anhydrous THF. The mixture was left stirring at room temperature overnight, then MeOH was added and the solvents removed in vacuo. A purple foam was obtained, which was purified by column chromatography on SiO<sub>2</sub>, eluting with 0-10 % MeOH in

dichloromethane. Finally recrystallization from acetonitrile/water afforded 45 mg of the title compound as a white solid (0.08 mmol, 21 % yield).

**Example 9: Synthesis of 1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea**



4-Aminonaphthol hydrochloride (4.40 g, 22.5 mmol, 1 equiv.) was dissolved in 30 mL anhydrous DMSO at room temperature and was treated with potassium tert-butoxide (5.05 g, 45.0 mmol, 2 equiv.). After 30 min 2,4-dichloropyrimidine (3.34 g, 22.5 mmol, 1 equiv.) in 12 mL anh. DMSO was added via cannula. Once the addition was complete, the mixture was heated to 60 °C for 3 h, then allowed to cool. Water (200 mL) was added and the product extracted with EtOAc (3 x 50 mL). Combined extracts were washed twice with water and once with brine, then dried (Na<sub>2</sub>SO<sub>4</sub>). A golden brown foam (6.60 g) was obtained after filtration and removal of solvents in vacuo. The crude product was

purified by column chromatography on SiO<sub>2</sub> using 35% EtOAc in hexanes as eluent. The purified product was isolated as an orange solid (4.68 g, 17.2 mmol, 76% yield).

The dichloropyrimidine-naphthylamine ether from above (1.04 g, 3.83 mmol, 1 equiv.) was dissolved in 100 mL dichloromethane and 75 mL of a saturated aqueous solution of sodium bicarbonate was added. The mixture was cooled to 0 °C. Without stirring, phosgene (~2 M in toluene, 6.7 mL, 13.4 mmol, 3.5 equiv.) was added via syringe to the organic layer in one portion. Stirring was resumed for 20 min, then the layers were separated. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and the solvent was removed in vacuo, leaving ~ 5 mL of toluene. To this residue was immediately added tert-butyl-ortho-anisidine (687 mg, 3.83 mmol, 1 equiv.) in 18 mL anh. THF at room temperature, and the mixture was left stirring for 4 h. The solvents were then removed in vacuo leaving a yellow solid, which was triturated to a white powder in hot EtOAc. The intermediate chloropyrimidine-urea was thus isolated (1.23 g, 2.58 mmol, 67 % yield).

The final substitutions of the chloropyrimidine from above, to afford a number of different aminopyrimidines, were carried out in parallel, and are exemplified here with 2-aminomethylpyridine.

The chloropyrimidine-urea (70 mg, 0.147 mmol, 1 equiv.) was dissolved in 1 mL anhydrous THF. Triethylamine (21 uL, 0.147 mmol, 1 equiv.) was added, followed by a 1 M solution of 2-aminomethylpyridine in THF (0.15 mL, 0.15 mmol, 1 equiv.). The mixture was sealed in a pressure tube and heated to 75 °C for 96 h. Water was added and the product extracted with EtOAc and purified by column chromatography on SiO<sub>2</sub> using 3 % MeOH in dichloromethane. An orange foam was obtained and the product was further purified by recrystallization from hot CH<sub>3</sub>CN to provide the title compound (29 mg), mp 148-150 °C.

## ASSESSMENT OF BIOLOGICAL PROPERTIES

**Inhibition of TNF Production in THP Cells**

5 The inhibition of cytokine production can be observed by measuring inhibition of TNF $\alpha$  in lipopolysaccharide stimulated THP cells (for example, see W. Prichett *et al.*, 1995, *J. Inflammation*, 45, 97). All cells and reagents were diluted in RPMI 1640 with phenol red and L-glutamine, supplemented with additional L-glutamine (total: 4 mM), penicillin and streptomycin (50 units/ml each) and fetal bovine serum (FBS, 3%) (GIBCO, all conc.

10 final). Assay was performed under sterile conditions; only test compound preparation was nonsterile. Initial stock solutions were made in DMSO followed by dilution into RPMI 1640 2-fold higher than the desired final assay concentration. Confluent THP.1 cells ( $2 \times 10^6$  cells/mL, final conc.; American Type Culture Company, Rockville, MD) were added to 96 well polypropylene round bottomed culture plates (Costar 3790; sterile)

15 containing 125  $\mu$ L test compound (2 fold concentrated) or DMSO vehicle (controls, blanks). DMSO concentration did not exceed 0.2% final. Cell mixture was allowed to preincubate for 30 min, 37°C, 5% CO<sub>2</sub> prior to stimulation with lipopolysaccharide (LPS; 1  $\mu$ g/mL final; Siga L-2630, from E.coli serotype 0111.B4; stored as 1 mg/mL stock in endotoxin screened distilled H<sub>2</sub>O at -80°C). Blanks (unstimulated) received H<sub>2</sub>O vehicle;

20 final incubation volume was 250  $\mu$ L. Overnight incubation (18 - 24 hr) proceeded as described above. Assay was terminated by centrifuging plates 5 min, room temperature, 1600 rpm (400 x g); supernatants were transferred to clean 96 well plates and stored - 80°C until analyzed for human TNF $\alpha$  by a commercially available ELISA kit (Biosource #KHC3015, Camarillo, CA). Data was analyzed by non-linear regression (Hill equation)

25 to generate a dose response curve using SAS Software System (SAS institute, Inc., Cary, NC). The calculated IC<sub>50</sub> value is the concentration of the test compound that caused a 50% decrease in the maximal TNF $\alpha$  production. Preferred compounds from those found in Table I and in the examples will exhibit an IC<sub>50</sub> < 10  $\mu$ M.

**Inhibition of other cytokines**

By similar methods using peripheral blood monocytic cells, appropriate stimuli, and commercially available ELISA kits (or other method of detection such as  
5 radioimmunoassay), for a particular cytokine, inhibition of IL-1, G M-CSF, IL-6 and IL-8 can be demonstrated (for example, see J.C. Lee *et al.*, 1988, *Int. J. Immunopharmacol.*, 10, 835).

**What is claimed is**

1. A compound selected from the group consisting of:

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-isopropyl-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2,6-dimethyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-3-[1,2,4]triazol-4-yl-phenyl)-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-oxo-2H-pyran-4-yloxy)-naphthalen-1-yl]-urea;

5-tert-Butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-benzoic acid;

Carbonic acid 5-tert-butyl-2-methoxy-3-{3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-ureido}-phenyl ester methyl ester;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(4-isopropylamino-[1,3,5]triazin-2-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[4-(cyclopropylmethyl-amino)-[1,3,5]triazin-2-yloxy]-naphthalen-1-yl}-urea;

1-[4-(4-Amino-[1,3,5]triazin-2-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-([1,3,5]triazin-2-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-cyclopropylamino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-ethylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-methyl-2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

1-[4-(2-Amino-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-cyclopentylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(cyclopropylmethyl-amino)-6-methoxy-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-[4-(2-Benzylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

1-[4-(2-sec-Butylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-methoxy-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-dimethylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-pyrrolidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(6-methyl-2-pyrrolidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-ethoxy-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-morpholin-4-yl-ethoxy)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-dimethylamino-ethoxy)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-[4-(2-Benzylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-3-[1,2,4]triazol-4-yl-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-methanesulfinyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-methylsulfonyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(2-Methoxy-5-trimethylsilanyl-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-methoxy-phenyl)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(3-methoxy-phenyl)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-phenyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

4-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidine-2-carboxylic acid methyl ester;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-cyano-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(tetrahydro-pyran-4-yloxy)-naphthalen-1-yl]-urea

or the pharmaceutically acceptable derivatives thereof.

2. A compound selected from the group consisting of:

1-[5-tert-Butyl-3-(1,1-dioxo-1-lambda-6-isothiazolidin-2-yl)-2-methoxy-phenyl]-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea;

N-(3-{3-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide;

N-(3-{3-[4-(2-Amino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-3-{3-[4-(2-cyano-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-2-methoxy-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(tetrahydropyran-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-methyl-2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;

N-[5-tert-Butyl-3-(3-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yloxy]-naphthalen-1-yl]-ureido)-2-methoxy-phenyl]-methanesulfonamide;

N-[5-tert-Butyl-3-(3-{4-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl]-ureido)-2-methoxy-phenyl]-methanesulfonamide;

N-{5-tert-Butyl-2-methoxy-3-[3-(4-{2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-ureido]-phenyl}-methanesulfonamide;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-pyrrolidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide

or the pharmaceutically acceptable derivatives thereof.

3. A compound selected from the group consisting of:

1-[5-tert-butyl-2-(2-hydroxy-4-methyl-phenyl)-2H-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-{4-[2-(hydroxy)ethoxy]-naphthalen-1-yl}-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-{4-[2-oxo-2-(morpholin-4-yl)-ethoxy]-naphthalen-1-yl}-urea;

1-[5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl]-3-{4-[hydroxy]-naphthalen-1-yl}-urea

or the pharmaceutically acceptable derivatives thereof.

4. A compound selected from the group consisting of:

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-isopropylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-cyclopropylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(1-phenyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(pyridin-4-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[2-(4-methyl-piperazin-1-yl)-ethylamino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-pyrrolidin-1-yl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-oxo-tetrahydro-furan-3-ylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(tetrahydro-furan-3-ylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-methyl-2-[(tetrahydro-furan-2-yl)methyl]-amino}-pyrimidin-4-yloxy)-naphthalen-1-yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-methoxy-1-methyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

2-(4-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidin-2-ylamino)-propionamide;

2-(4-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidin-2-ylamino)-N-methyl-propionamide;

2-(4-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidin-2-ylamino)-N,N-dimethyl-propionamide;

2-(4-{4-[3-(5-tert-Butyl-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidin-2-ylamino)-N,N-dimethyl-acetamide

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[1-(3-methoxy-phenyl)-ethylamino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;

1-(4-{2-[1-(2-Bromo-phenyl)-ethylamino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(4-diethylamino-1-methyl-butylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(4-methoxy-benzylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(3-chloro-benzylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-{4-[2-(Benzyl-methyl-amino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{2-[(2-dimethylamino-ethyl)-methyl-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;

1-[4-(2-Benzylamino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-methyl-2-(1-phenyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-(4-{6-methyl-2-[(pyridin-2-yl)methyl]-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(2-dimethylamino-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[6-methyl-2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-[4-(2-dimethylamino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-morpholin-4-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(1-phenyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[6-methyl-2-(1-phenyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

N-{5-tert-Butyl-2-methoxy-3-[3-(4-{2-[(pyridin-3-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-ureido]-phenyl}-methanesulfonamide;

N-[5-tert-Butyl-3-(3-{4-[2-(2-dimethylamino-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-2-methoxy-phenyl]-methanesulfonamide;

N-[5-tert-Butyl-3-(3-{4-[2-(2-dimethylamino-ethylamino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-2-methoxy-phenyl]-methanesulfonamide;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[6-methyl-2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

N-(5-tert-Butyl-3-{3-[4-(2-dimethylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-2-methoxy-phenyl)-methanesulfonamide;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-piperidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;

N-{5-tert-Butyl-3-[3-(4-{2-[(2-dimethylamino-ethyl)-methyl-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-ureido]-2-methoxy-phenyl}-methanesulfonamide;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(tetrahydrofuran-3-ylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(2-methoxy-1-methyl-ethylamino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

2-(4-{4-[3-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidin-2-ylamino)-N-methyl-propionamide;

2-(4-{4-[3-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidin-2-ylamino)-N,N-dimethyl-propionamide;

N-{5-tert-Butyl-2-methoxy-3-[3-(4-{2-[(pyridin-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-ureido]-phenyl}-methanesulfonamide;

N-{5-tert-Butyl-2-methoxy-3-[3-(4-{6-methyl-2-[(tetrahydro-furan-2-ylmethyl)-amino]-pyrimidin-4-yloxy}-naphthalen-1-yl)-ureido]-phenyl}-methanesulfonamide;

N-(5-tert-Butyl-2-methoxy-3-{3-[4-(6-methyl-2-pyrrolidin-1-yl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide;

2-(5-tert-Butyl-2-methoxy-3-{3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;

2-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-pyrrolidin-1-ylmethyl-pyridin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;

2-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(pyrrolidine-1-carbonyl)-pyridin-4-yloxy]-naphthalen-1-yl}-ureido)-phenylamino]-thiazole-4-carboxylic acid ethyl ester;

2-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylaminomethyl-pyridin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;

2-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylcarbamoyl-pyridin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;

2-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylamino-pyridin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;

1-{5-tert-Butyl-2-methoxy-3-[4-(pyrrolidine-1-carbonyl)-thiazol-2-ylamino]-phenyl}-3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-urea;

1-[5-tert-Butyl-2-methoxy-3-(4-pyrrolidin-1-ylmethyl-thiazol-2-ylamino)-phenyl]-3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-urea;

2-(5-tert-Butyl-2-methoxy-3-{3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;

2-(3-{3-[4-(2-Amino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-5-tert-butyl-2-methoxy-phenylamino)-thiazole-4-carboxylic acid ethyl ester;

2-(5-tert-Butyl-2-methoxy-3-{3-[4-(2-methylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid ethyl ester;

2-[5-tert-Butyl-3-(3-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-2-methoxy-phenylamino]-thiazole-4-carboxylic acid ethyl ester;

2-(5-tert-Butyl-2-methoxy-3-{3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-phenylamino)-thiazole-4-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide;

1-{5-tert-Butyl-2-methoxy-3-[4-(pyrrolidine-1-carbonyl)-thiazol-2-ylamino]-phenyl}-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-[5-tert-Butyl-2-methoxy-3-(4-pyrrolidin-1-ylmethyl-thiazol-2-ylamino)-phenyl]-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-[5-tert-Butyl-2-methoxy-3-(4-pyrrolidin-1-ylmethyl-thiazol-2-ylamino)-phenyl]-3-[4-(2-isopropylamino-pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-{5-tert-Butyl-2-methoxy-3-[4-(pyrrolidine-1-carbonyl)-thiazol-2-ylamino]-phenyl}-3-{4-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-[5-tert-Butyl-2-methoxy-3-(4-pyrrolidin-1-ylmethyl-thiazol-2-ylamino)-phenyl]-3-{4-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-[5-tert-Butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-urea;

1-[5-tert-Butyl-3-(3-dimethylaminomethyl)-2-methoxy-phenyl]-3-[4-(pyridin-4-yloxy)-naphthalen-1-yl]-urea;

1-[5-tert-Butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-3-[4-(2-dimethylaminomethyl-pyridin-4-yloxy)-naphthalen-1-yl]-urea;

1-[5-tert-Butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-3-[4-(pyrimidin-4-yloxy)-naphthalen-1-yl]-urea;

1-[4-(2-Amino-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-[5-tert-butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-urea;

1-[4-(2-Amino-6-methyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-[5-tert-butyl-3-(3-dimethylamino-pyrrolidin-1-ylmethyl)-2-methoxy-phenyl]-urea;

1-(5-tert-Butyl-3-dimethylaminomethyl-2-methoxy-phenyl)-3-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

1-(5-tert-Butyl-3-dimethylaminomethyl-2-methoxy-phenyl)-3-{4-[2-(cyclopropylmethyl-amino)-6-methyl-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(2-methoxy-phenyl)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

4-{4-[3-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenyl)-ureido]-naphthalen-1-yloxy}-pyrimidine-2-carboxylic acid methyl ester;

1-[4-(2-Acetyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-3-(5-tert-butyl-2-methoxy-phenyl)-urea;

N-(3-{3-[4-(2-Acetyl-pyrimidin-4-yloxy)-naphthalen-1-yl]-ureido}-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide;

1-(5-tert-Butyl-2-methoxy-phenyl)-3-{4-[2-(1-pyrrolidin-1-yl-ethyl)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea;

N-[5-tert-Butyl-2-methoxy-3-(3-{4-[2-(1-pyrrolidin-1-yl-ethyl)-pyrimidin-4-yloxy]-naphthalen-1-yl}-ureido)-phenyl]-methanesulfonamide;

1-(2-methoxy-5-trimethylsilanyl-phenyl)-3-{4-[2-(cyclopropylmethyl-amino)-pyrimidin-4-yloxy]-naphthalen-1-yl}-urea

or the pharmaceutically acceptable derivatives thereof.

- 5 5. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to claims 1, 2, 3 or 4.
6. A method of treating a cytokine mediated disease or condition which comprises administering to a patient in need of such treatment a therapeutically effective amount of  
10 a compound according to claims 1, 2, 3 or 4.
7. The method according to claim 6 wherein cytokine mediated disease or condition is selected from rheumatoid arthritis, osteoarthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Guillain-Barre syndrome, psoriasis, graft versus host disease, systemic  
15 lupus erythematosus, percutaneous transluminal coronary angioplasty, diabetes, toxic shock syndrome, Alzheimer's disease, acute and chronic pain, contact dermatitis,

atherosclerosis, traumatic arthritis, glomerulonephritis, reperfusion injury, sepsis, bone resorption diseases, chronic obstructive pulmonary disease, congestive heart failure, asthma, stroke, myocardial infarction, thermal injury, adult respiratory distress syndrome (ARDS), multiple organ injury secondary to trauma, dermatoses with acute inflammatory components, acute purulent meningitis, necrotizing enterocolitis, syndromes associated with hemodialysis, leukopheresis and granulocyte transfusion.

8. The method according to claim 7 wherein the disease is selected from rheumatoid arthritis, osteoarthritis, Crohn's disease, psoriasis, ulcerative colitis, osteoporosis, chronic obstructive pulmonary disease, percutaneous transluminal coronary angioplasty and congestive heart failure.

9. The method according to claim 8 wherein the disease is selected from rheumatoid arthritis, Crohn's disease, psoriasis, chronic obstructive pulmonary disease, percutaneous transluminal coronary angioplasty and congestive heart failure.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/14733

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/34 A61K31/505 C07D251/42 C07D239/47 C07D417/12  
C07D401/12 C07D231/40 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 55139 A (BOEHRINGER INGELHEIM PHARMA) 21 September 2000 (2000-09-21) page 68-85 -page 107-121; claim 17	1,2,4,5
X	page 17-18	3
X	WO 00 43384 A (BOEHRINGER INGELHEIM PHARMA) 27 July 2000 (2000-07-27) example 4	3
P,X	WO 01 36403 A (BOEHRINGER INGELHEIM PHARMA ;BREITFELDER STEFFEN (US); HAO MING HO) 25 May 2001 (2001-05-25) the whole document	1,2,4,5



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

3 July 2002

Date of mailing of the international search report

11/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 02/14733

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 6-9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

annex on patent family members

International Application No

PCT/US 02/14733

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0055139	A	21-09-2000	AU 2881700 A	04-10-2000
			BG 105880 A	31-05-2002
			BR 0008922 A	15-01-2002
			CN 1349509 T	15-05-2002
			CZ 20013289 A3	16-01-2002
			EP 1165516 A2	02-01-2002
			NO 20014412 A	11-09-2001
			TR 200102817 T2	21-05-2002
			WO 0055139 A2	21-09-2000
			US 6358945 B1	19-03-2002
			US 2002055507 A1	09-05-2002
WO 0043384	A	27-07-2000	AU 1752200 A	07-08-2000
			BG 105653 A	31-01-2002
			BR 9916930 A	30-10-2001
			CN 1333767 T	30-01-2002
			CZ 20012635 A3	14-11-2001
			EP 1147104 A1	24-10-2001
			NO 20013559 A	18-07-2001
			SK 10192001 A3	03-12-2001
			WO 0043384 A1	27-07-2000
			US 6319921 B1	20-11-2001
			US 6333325 B1	25-12-2001
			US 2002058678 A1	16-05-2002
			US 6329415 B1	11-12-2001
			US 2002065285 A1	30-05-2002
			US 6372773 B1	16-04-2002
WO 0136403	A	25-05-2001	AU 1617901 A	30-05-2001
			WO 0136403 A1	25-05-2001

10